Yifan Pharmaceutical (002019.SZ): N-3C01 injection approved for clinical trials.

18:36 08/12/2025

Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Xinzhu Biotechnology Co., Ltd. (referred to as "Hefei Xinzhu"), recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. This approval allows Hefei Xinzhu to conduct clinical trials on the investigational new large molecule drug N-3C01 injection (referred to as "N-3C01") for the treatment of advanced solid tumors and non-muscle-invasive bladder cancer (NMIBC).

Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Xinzhu Biotechnology Co., Ltd. (referred to as "Hefei Xinzhu"), recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The approval allows Hefei Xinzhu to conduct clinical trials on the investigational new macromolecular drug N-3C01 injection (referred to as "N-3C01") for the treatment of advanced solid tumors and non-muscle-invasive bladder cancer (NMIBC).

New Stock Outlook | With the support of more than ten state-owned shareholders, can the merger and acquisition growth story of Tiandi HeXing earn market approval?

Guosen: The final mindset of asset trend convergence.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

New Stock Outlook | With the support of more than ten state-owned shareholders, can the merger and acquisition growth story of Tiandi HeXing earn market approval?

Guosen: The final mindset of asset trend convergence.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.